Aside from the fact that they are ineffective for COPD, these inhalers can pose risks including masking symptoms and increasing treatment side effects. There are only a few OTC inhalers available.

has been approved since 2020 in the US as a maintenance treatment used to reduce exacerbations in people living with chronic obstructive pulmonary disease (COPD). Sales of Breztri were $677 ...

Various types of inhalers, including short- and long-lasting options, are available for managing chronic obstructive pulmonary disease (COPD ... is the percentage of treatment costs that a ...